Independent pharmacies are one of the most overlooked acquisition targets in lower-middle-market ETA. The average buyer pool is thin: licensed pharmacists who understand the business lack capital, and most financial buyers don't know how to underwrite one. That gap creates deals. If you can operate a pharmacy or partner with a licensed pharmacist manager, you're competing in a market with almost no one else at the table.
According to Dealflow OS's independent pharmacy acquisition guide, independent pharmacies typically trade at 3x to 6x EBITDA, plus inventory at wholesale cost. The multiple depends on script volume, PBM contract stability, and whether the pharmacy offers services chains can't replicate. That range reflects real market data from closed deals, not broker optimism.
Before you model a deal, understand what you're actually buying.
Why pharmacies work as acquisition targets
Prescription revenue is non-discretionary. Patients filling prescriptions for chronic conditions, diabetes, hypertension, cardiovascular disease, refill monthly, indefinitely, and mostly through insurance. That is as close to contractually recurring revenue as retail healthcare gets.
Patient stickiness is among the highest of any healthcare business. People do not switch pharmacies the way they switch gyms or accountants. A pharmacy serving a community for 20 years has a patient base with deeply embedded behavioral patterns. The seller leaving does not change where patients pick up their medication.
Seller demographics are favorable. The average independent pharmacy owner is in their mid-50s to mid-60s. Many have operated for 20 to 30 years. When they retire, the buyer pool is thin. Buyers who arrive credentialed and capitalized face minimal competition.
Long-term care contracts create institutional revenue. A pharmacy serving nursing homes and assisted living facilities under LTC contracts has a revenue floor that survives retail patient attrition. One 100-bed nursing facility contract can generate $40,000 to $80,000 in monthly prescription revenue. That is not walk-in traffic you can lose to a Walgreens across the street.
Compounding pharmacies command multiple premiums. FDA-registered or state-accredited compounding operations serve patients whose medications cannot be filled by chains: custom hormone therapies, pediatric formulations, veterinary compounds, dermatology preparations. Compounding revenue carries higher margins than standard dispensing and attracts patients who are not comparison-shopping.
What independent pharmacies are worth
The 3x to 6x EBITDA range is not arbitrary. The spread is driven by specific operational factors.
Prescription volume matters. Rxs per day is the fundamental productivity metric. A pharmacy filling 150 to 200 prescriptions per day has a different revenue profile than one filling 80. More important than the absolute number is the trend: a pharmacy growing at 3 to 5 percent annually is worth more than a flat pharmacy of equivalent size.
PBM contract status determines revenue stability. Pharmacy Benefit Manager contracts with CVS Caremark, Express Scripts, and OptumRx determine what the pharmacy gets paid per prescription. In-network status with major PBMs is a prerequisite for maintaining volume. Patients covered by employer-sponsored insurance are typically required to use in-network pharmacies. Confirm in-network status and review the reimbursement rate schedule before building any model.
A deal benchmark: a licensed pharmacist in Georgia acquired an independent pharmacy for $1.1 million in 2023 at 4.8x EBITDA on $229,000 in adjusted earnings, with $110,000 down and SBA 7(a) financing covering the rest. The seller had owned the pharmacy for 26 years, had 1,400 active prescription patients, and was retiring with no succession plan. That deal profile is the norm, not the exception.
Specialty services add meaningful value. Compounding operations, medication therapy management programs, and immunization programs carry a multiple premium of 0.5x to 1.0x over equivalent-EBITDA pharmacies without them. Front-end retail typically generates 15 to 25 percent of revenue with lower margins, but it signals a well-run community operation.
The Sofer Advisors 2026 pharmacy valuation guide breaks the matrix this way: LTC contracts, compounding, and 150-plus Rxs per day with growing volume commands 5.0x to 6.0x. A strong retail base with multiple PBM contracts lands at 4.0x to 5.0x. A straightforward independent with 80 to 150 Rxs per day and no specialty services trades closer to 3.0x to 4.0x.
Financing the acquisition
SBA 7(a) is the primary path for most pharmacy acquisitions. Expect 10 to 20 percent down, a debt service coverage ratio of at least 1.2x, and lenders who normalize cash flow for DIR fees and PBM clawbacks before underwriting. Seller notes covering 10 to 20 percent of the purchase price are common. They bridge valuation gaps and improve DSCR for the bank. Most sellers who have owned a pharmacy for decades and have no heir understand the value of carrying a note to get a deal closed.
DIR fees require scrutiny. Direct and Indirect Remuneration fees are clawbacks that Medicare Part D PBMs can levy after the point of sale, reducing the pharmacy's actual net reimbursement. The CMS reformed point-of-sale DIR fee rules in 2024, but their historical impact on cash flow is part of every normalization conversation. Lenders who know pharmacy underwrite DIR fees into their DSCR calculations. Lenders who don't will misprice the deal.
For a detailed breakdown of SBA acquisition financing mechanics, see how to buy a business with seller financing, which covers seller note structures and DSCR optimization.
Due diligence priorities
Pharmacy due diligence has industry-specific failure modes that standard QoE processes miss.
PBM contracts are the biggest risk. Verify in-network status with every PBM and request the audit history for the last three years. A pharmacy that has been audited for prescription irregularities or clawbacks carries recurrence risk. PBM contracts are not automatically assignable to a new owner; some require re-credentialing. Find out which contracts require re-credentialing and how long it takes before you set your closing timeline.
Patient retention modeling matters. A pharmacy's 1,400 active patients sounds stable. But what percentage has the owner built a personal relationship with over 26 years? How much of that patient loyalty transfers to a new owner versus walking two miles to a CVS? The answer varies by community and service offering. Get a sense of it before you close.
Normalize for market-rate pharmacist salary. Many owner-operated independent pharmacies have the owner working as the primary pharmacist at below-market compensation. Add a market-rate pharmacist salary back into your EBITDA normalization. If that adjustment destroys your return, you bought an operating job, not a business.
Review long-term care facility contracts carefully. LTC contracts can be terminated if the pharmacy loses in-network status with a key PBM, fails a state board inspection, or the facility switches management companies. The revenue is institutional, but the contract terms matter.
The licensing trap that kills closings
DEA registration and state board pharmacy permits do not transfer to a new owner. They must be applied for fresh. That process takes 45 to 90 days.
If you try to close a pharmacy acquisition without a DEA registration in place for the incoming entity, you cannot legally operate. The business goes dark until the registration arrives. That outcome ends deals, triggers MAC pricing risk from PBMs, and drives patients to competitors permanently.
Start the DEA registration application the day you sign the letter of intent. Do not wait for due diligence to complete. The permit is not transferable, and the timeline is not negotiable.
Structure the transition so the seller remains available for 90 to 180 days post-close. Patient handoffs, PBM credentialing support, and facility relationship introductions all require the prior owner's involvement. Make it a condition of the purchase agreement.
The operator's verdict
Independent pharmacies are not glamorous. The search fund community has spent more time chasing software companies and B2B services businesses than pharmacy acquisitions. That is exactly why the opportunity exists. Retiring pharmacists with 25 years of patient relationships and no succession plan are motivated sellers. The buyer pool is thin. The licensing complexity scares away unsophisticated buyers.
If you can clear the regulatory hurdles, model the PBM contracts correctly, and structure a transition that keeps the patient base intact, you are buying a business with recurring, non-discretionary revenue and a seller who has no other exit. That combination does not come with a bidding war.
Study the valuation mechanics before you look at deal flow. Know what DIR fees are and how lenders underwrite them. Understand which PBM contracts require re-credentialing. Get your DEA registration application in motion before you think you need it.
The operators who close pharmacy deals are the ones who did the work before anyone else at the table understood the business well enough to compete.
Frequently Asked Questions
What EBITDA multiple do independent pharmacies typically sell for?
Independent pharmacies typically sell for 3x to 6x EBITDA, plus inventory at wholesale cost. The multiple depends on prescription volume, PBM contract stability, long-term care facility contracts, and specialty services like compounding. Pharmacies with LTC contracts and compounding operations command 5x to 6x EBITDA. Straightforward retail-only pharmacies trade closer to 3x to 4x.
Can you use SBA financing to buy an independent pharmacy?
Yes. SBA 7(a) loans are the primary financing path for most pharmacy acquisitions. Lenders typically require 10 to 20 percent down and a debt service coverage ratio of at least 1.2x. Lenders normalize cash flow for DIR fees and PBM clawbacks before underwriting. Seller notes covering 10 to 20 percent of the purchase price are common to bridge valuation gaps and improve DSCR.
Why does DEA registration matter when buying a pharmacy?
DEA registration and state board pharmacy permits cannot be transferred to a new owner. They must be applied for fresh and take 45 to 90 days to process. If you close without a DEA registration in place for the incoming entity, you cannot legally operate the business. Start the application the day you sign the letter of intent.
What is the biggest due diligence risk in pharmacy acquisitions?
PBM contract stability is the biggest risk. Pharmacy Benefit Manager contracts determine what the pharmacy gets paid per prescription. Some contracts require re-credentialing when ownership changes, which can delay revenue recognition. Audit history showing clawbacks or compliance issues signals recurrence risk. Verify in-network status with every PBM and request the audit history for the last three years before signing an LOI.
